Dow opens 407 pts higher as oil, yields ease ahead of Trump‑Xi summit

The Dow opened 407 points, or 0.79%, higher at 52,089.54, while the S&P 500 gained 0.7% and the Nasdaq rose 1.1% as the 10-year Treasury yield fell more than 3bps to 4.957% and WTI crude dropped about 3% to $97.09 per barrel. Greenland-linked equities surged following President Trump's Arctic security agreement, with Greenland Energy up more than 144%, Greenland Mines nearly 70%, and Critical Metals over 30%. Investors are positioning ahead of a Trump-Xi summit focused on tariffs, critical minerals and AI, while persistent risks include yields near 5%, oil around $100, Middle East tensions and the Fed's recent rate hike.

Analysis

The sharpest signal is not the broad equity bounce but the re-pricing of duration-sensitive earnings under a still-restrictive rate regime. A modest intraday decline in yields does little for homebuilder affordability if mortgage rates remain above the level at which buyers can absorb new-home price inflation; PHM faces both order-rate risk and multiple compression if incentives must rise to preserve volumes. The cleaner second-order beneficiary is not necessarily WFC, whose mortgage banking gains are offset by funding-cost and credit-cycle sensitivity, but apartment REITs and rental-oriented operators if would-be buyers remain renters for another two to four quarters.

CRML, GLND and GRML should be treated as event-driven liquidity vehicles rather than investable proxies for a multi-year minerals buildout. Security agreements, resource diplomacy and summit language do not create reserve value without financing, permits, offtake contracts and processing capacity; the likely bottleneck is Western refining and separation, where established rare-earth supply-chain exposure (MP, LYC.AX) offers more durable economics. A favorable U.S.-China communiqué could perversely deflate the scarcity premium in these small-cap names by reducing perceived supply disruption.

For WBD, regulatory concessions improve closing probability but do not settle the central valuation question: whether remedies preserve sufficient synergy to justify a strategic buyer's price. The relevant trade is the merger spread versus deal-break risk, not a directional media bet; prolonged state-level review can erode annualized returns quickly. NVO's reaction is potentially more actionable on a 6-18 month horizon: a small launch variance matters less than whether oral GLP-1 access broadens the treated population without materially cannibalizing injectable pricing, so upcoming prescription, gross-to-net and capacity disclosures matter more than headline sales comparisons.

The consensus risk is assuming softer oil and yields are unambiguously risk-on. If the decline reflects a temporary geopolitical de-escalation while inflation expectations remain elevated, the market can reprice back toward higher real yields after the summit. That would pressure expensive growth, housing and leveraged transaction stories simultaneously; the near-term rally is therefore better used to establish hedges than to chase index beta.

Key Decisions for Investors

• Maintain a 1-3 month short PHM versus long MAA or AVB: sustained mortgage rates above 6.75% should keep new-home incentives and cancellation risk elevated while rental demand tightens. Target 10-15% relative downside; cover if the 10-year Treasury yield holds below 4.50% for two weeks or PHM raises order/community guidance.
• Do not chase CRML, GLND or GRML after vertical moves. Set an alert for a disclosed, funded government award or binding offtake with a credible processor; absent that evidence, any long should be a tightly sized tactical position only, with liquidity and dilution risk dominating fundamental upside.
• Use WBD only as a defined-risk merger-spread trade after confirming consideration, outside date and remedy terms; size for a 6-12 month regulatory timeline. Exit on an adverse California AG filing or if required production/divestiture commitments materially reduce implied deal value; avoid treating PSKY/WBD as a clean directional pair before terms are verified.
• Accumulate NVO on weakness over 3-6 months only if next-quarter oral prescription growth and gross-margin guidance confirm that access expansion is not discount-led. A guidance cut tied to pricing, rather than launch timing, would falsify the thesis and argues for rotating exposure toward LLY.
• Keep a tactical overweight in quality duration hedges rather than broad equities: long TLT calls or receive fixed against a small XLE hedge for the next 1-3 months. The hedge protects a renewed inflation/geopolitical oil spike; reassess if Brent closes sustainably below $90 or the next inflation release materially undershoots expectations.